1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
PHS 2024-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH) / National Institute of General Medical Sciences (NIGMS).
This omnibus solicitation supports small businesses engaged in research and development with strong commercialization potential, addressing challenges faced by NIH populations experiencing health disparities. This includes technology and service innovations.
Get alerted about grants like this
Get emailed when new opportunities from “National Institutes of Health (NIH) / National Institute of General Medical Sciences (NIGMS)” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: U.S.-owned and operated small businesses (typically under 500 employees) engaged in research and development. Priority is given to applications targeting the NIH Minority Health and Health Disparities Strategic Plan and Research Framework. Confirm the full requirements in the official notice before applying.
The current listing shows phase I awards range from $50,000 to $275,000; Phase II awards range from $400,000 to $1.8 million (NIMHD encourages contacting program official for awards exceeding waiver amounts). Verify award ceilings, matching requirements, and allowable costs in the official notice.
PHS 2024-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) is funded by National Institutes of Health (NIH) / National Institute of General Medical Sciences (NIGMS). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Commercialization Readiness Pilot (CRP) Program (PAR-27-098) is sponsored by National Institutes of Health (NIH) / National Institute of General Medical Sciences (NIGMS). This program facilitates the transition of previously funded SBIR and STTR Phase 2 and Phase 2B projects to the commercialization stage by providing additional support for technical assistance and late-stage product development.
NIH Small Business Innovation Research (SBIR) Program (Parent SBIR [R43/R44] Clinical Trial Not Allowed) (PA-24-245) / (Parent SBIR [R43/R44] Clinical Trial Required) (PA-24-246) is sponsored by National Institutes of Health (NIH) / National Institute of General Medical Sciences (NIGMS). NIGMS participates in the NIH SBIR program, which supports small businesses engaging in research and development activities with strong potential for commercialization.
Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Optional) (PA-20-272) is sponsored by National Institutes of Health (NIH) / National Institute of General Medical Sciences (NIGMS). These administrative supplements are intended to increase the diversity of the research workforce by supporting individuals from underrepresented groups.
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science (SCH) is sponsored by National Science Foundation (NSF) & National Institutes of Health (NIH). This interagency program supports high-risk, high-reward advances in AI and data science for biomedical and public health research. Projects must cross disciplinary boundaries.
The NIH Common Fund launched PRIMED-AI — Precision Medicine with AI: Integrating Imaging with Multimodal Data — as five coordinated funding opportunities (RFA-RM-27-011 through -015) that build a full pipeline from standards to clinic. Here is how the Playbook, Data-to-Model partnerships, Model-to-Clinic translation, Validation Center, and Logistics Center fit together, what each pays, who is eligible, and how to position before the October 2026 deadlines.
Read articleAfter a rare gap with zero active omnibus NOFOs, NIH has reissued its SBIR/STTR parent announcements — collapsing four solicitations into two, adding a Strategic Breakthrough bridge and a Commercialization Readiness Pilot, and reopening the funnel with a September 5, 2026 receipt date. Here are the exact solicitation numbers, the new budget ceilings, what actually changed, and how a small business should sequence its submission.
Read articleAfter an authorization lapse froze new SBIR/STTR awards for five months, NIH reopens its submission window on August 5, 2026, with a first standard deadline of September 8. Phase I awards run to $323,090, Phase II to $2,153,927, with published waiver topics reaching $700,000 and $3 million — and a new Phase IIB Strategic Breakthrough lane up to $30 million. Here is how the restarted omnibus is structured, why applying early matters more than usual this cycle, and how to position a life-science startup to win.
Read article